Takuo Emoto

Takuo Emoto

Auto-generated profile, based on publicly available information

Takuo Emoto

Kobe University Graduate School of Medicine

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
TETakuo Emoto
Takuo Emoto
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
TYTomoya Yamashita
Tomoya Yamashita
TTTomofumi Takaya
Tomofumi Takaya
TSTakahiro Sawada
Takahiro Sawada
KHKen-Ichi Hirata
Ken-Ichi Hirata

22 April 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
DTDanya Thayaparan
Danya Thayaparan
TETakuo Emoto
Takuo Emoto
AKAniqa B. Khan
Aniqa B. Khan
RBRickvinder Besla
Rickvinder Besla
HHHomaira Hamidzada
Homaira Hamidzada
CRClinton S. Robbins
Clinton S. Robbins

1 December 2022 in Hypertension
Verified
Journal Article
Open access
PDF file
RSRyohei Shinohara
Ryohei Shinohara
HNHitomi Nakashima
Hitomi Nakashima
TETakuo Emoto
Takuo Emoto
TYTomoya Yamashita
Tomoya Yamashita
YSYoshihiro Saito
Yoshihiro Saito
KHKen-Ichi Hirata
Ken-Ichi Hirata
Background: Abdominal aortic aneurysm (AAA) is a life-threatening cardiovascular disease characterized by dilated abdominal aorta. Immune cells have been shown to contribute to the development of AAA, and that the gut microbiota is associated with numerous diseases, including cardiovascular diseases, by regulating immune systems or metabolic pathways of the host. However, the interaction between the gut microbiota and AAA remains unknown. Methods: Apolipoprotein E–deficient male mice were fed a high-cholesterol diet and divided into three groups: the control group was maintained under normal water (control group), the oral AVNM group was maintained under drinking water supplemented with ampicillin, vancomycin, neomycin, and metronidazole, and the i.p. AVNM group was injected AVNM intraperitoneally. After 1 week of pretreatment with antibiotics, these mice were administrated Ang II via subcutaneous osmotic pumps for 4 weeks and euthanized to evaluate AAA formation. Results: Depletion of gut microbiota by oral AVNM ameliorated the incidence of AAAs (control group: 58.9% versus oral AVNM group: 28.6% versus i.p. AVNM group: 75.0%, P = 0.0005) and prevented death due to ruptured aneurysms (control group: 11% versus oral AVNM group: 0% versus i.p. AVNM group: 15%). Oral AVNM suppressed monocyte storage in the spleen, but not in other organs. Despite possessing a higher level of cholesterol, recruitment of monocytes into the suprarenal aorta was suppressed in the oral AVNM group. In AVNM drinking mice, NOD1 ligand, a kind of PRR ligands, increased the development of AAAs and accumulation of macrophages in the aortae. Conclusions: The gut microbiota plays a critical role in AAA formation. Therefore, regulation of the microbiota or the immune system can be a therapeutic approach for AAA.

2 December 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
YSYuya Suzuki
Yuya Suzuki
TETakuo Emoto
Takuo Emoto
SSShunsuke Sato
Shunsuke Sato
TYTakeshi Yoshida
Takeshi Yoshida
MSMitsuhiko Shoda
Mitsuhiko Shoda
KFKoji Fukuzawa
Koji Fukuzawa
Atrial fibrillation (AF) is strongly associated with strokes, heart failure, and increased mortality. This study aims to identify the monocyte–macrophage heterogeneity and interactions of these cells with non-immune cells, and to identify functional biomarkers in patients with AF. Therefore, we assess the single cell landscape of left atria (LA), using a combination of single cell and nucleus RNA-seq. Myeloid cells in LA tissue are categorized into five macrophage clusters, three monocyte clusters, and others. Cell-Chat analysis revealed that monocytes and IL1B+ macrophages send epidermal growth factor (EGF) signals to fibroblasts. Amphiregulin (AREG) is the most upregulated gene in monocytes and IL1B+ macrophages in the AF group, compared with healthy controls from other groups. Serum AREG levels are higher in patients with persistent AF. These data suggested that EGF signaling pathway could be a therapeutic target for AF and serum AREG levels provide an effective biomarker for predicting persistent AF.

1 September 2021 in International Journal of Cardiology
Verified
Journal Article
Closed access
TETakuo Emoto
Takuo Emoto
THTomohiro Hayashi
Tomohiro Hayashi
TTTokiko Tabata
Tokiko Tabata
TYTomoya Yamashita
Tomoya Yamashita
HWHikaru Watanabe
Hikaru Watanabe
KHKen-Ichi Hirata
Ken-Ichi Hirata

1 June 2025 in Hypertension
Verified
Journal Article
Closed access
NKNaoya Kuwahara
Naoya Kuwahara
MNManabu Nagao
Manabu Nagao
MSMasakazu Shinohara
Masakazu Shinohara
KKKenta Kaneshiro
Kenta Kaneshiro
TETakuo Emoto
Takuo Emoto
RTRyuji Toh
Ryuji Toh
BACKGROUND: ATP citrate lyase (ACLY) is a key enzyme in de novo lipogenesis that generates acetyl-CoA from citrate. Although fatty acids are required for energy production and biomass synthesis in the heart, the regulatory mechanisms of ACLY-mediated de novo lipogenesis in pathological cardiac fibroblasts remain unknown. The aim of this study was to investigate the biological role of ACLY in cardiac remodeling. METHODS: Adeno-associated virus serotype 9-mediated shRNA targeting Acly was intravenously injected into C57BL/6J male mice. The mice were subsequently continuously infused with a mixture of angiotensin II and phenylephrine. Cardiac phenotypes were evaluated via histological staining. Cell proliferation assays, stable isotope tracing with 13C-labeled glucose, and chromatin immunoprecipitation assays were performed using human cardiac fibroblasts. RESULTS: ACLY expression was upregulated in the heart sections of mice treated with angiotensin II/phenylephrine, in particular in fibrotic areas. Masson trichrome staining revealed that Acly gene silencing significantly reduced cardiac fibrosis in these mice. Both siRNA-mediated ACLY knockdown and pharmacological ACLY inhibition suppressed the proliferation and expression of fibrous proteins in cultured human cardiac fibroblasts stimulated with transforming growth factor-β. Mechanistically, ACLY inhibition reduced de novo lipogenesis, limiting the fatty acid supply essential for cellular growth and proliferation. It also decreased H3K9 and H3K27 acetylation, in addition to the presence of acetylated H3K9 and H3K27 at the promoter regions of fibrotic genes. CONCLUSIONS: Our findings demonstrate that ACLY plays an important role in maladaptive cardiac fibrosis. ACLY could be a novel therapeutic target to prevent the development of heart failure.